PVH
GNMX

Psagot Value Holdings’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Psagot Value Holdings’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,316
Closed -$5K – 336
2017
Q3 		$5K Buy
4,316
+373
+9% +$477 ﹤0.01% 300
2017
Q2 		$5K Buy
3,943
+134
+4% +$194 ﹤0.01% 296
2017
Q1 		$7K Sell
3,809
-530
-12% -$2.4K ﹤0.01% 311
2016
Q4 		$22K Sell
4,339
-1,681
-28% -$8.85K ﹤0.01% 290
2016
Q3 		$34K Sell
6,020
-1,702
-22% -$9.7K ﹤0.01% 273
2016
Q2 		$43K Sell
7,722
-4,099
-35% -$21.5K ﹤0.01% 257
2016
Q1 		$52K Sell
11,821
-3,112
-21% -$12.8K ﹤0.01% 296
2015
Q4 		$90K Sell
14,933
-2,197
-13% -$14.9K ﹤0.01% 295
2015
Q3 		$134K Buy
17,130
+3,812
+29% +$29.5K ﹤0.01% 264
2015
Q2 		$82K Buy
+13,318
New +$103K ﹤0.01% 306

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Psagot Value Holdings's GNMX Position: Q4 2017 in Review

Psagot Value Holdings sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2017, closing a stake of 4,316 shares — an estimated $5K sold.

Psagot Value Holdings first reported a position in GNMX in Q2 2015 and held it in 10 quarters. The position peaked at $134K in Q3 2015. 45 funds tracked by Wall St. Rank hold GNMX as of Q4 2017.

  • Psagot Value Holdings reported no remaining Aevi Genomic Medicine Inc position as of Q4 2017 after selling out during the quarter.
  • Psagot Value Holdings sold 4,316 Aevi Genomic Medicine Inc shares in Q4 2017, an estimated $5K.
  • Psagot Value Holdings first reported a position in Aevi Genomic Medicine Inc in Q2 2015 and held it in 10 quarters.
  • Psagot Value Holdings's Aevi Genomic Medicine Inc position peaked at $134K in Q3 2015.
  • 45 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2017.

Based on Psagot Value Holdings's 13F filing for Q4 2017, filed 8 Feb 2018.